Changliang Shan

ORCID: 0000-0002-4906-1686
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer, Hypoxia, and Metabolism
  • RNA modifications and cancer
  • Epigenetics and DNA Methylation
  • Hepatitis B Virus Studies
  • Metabolism, Diabetes, and Cancer
  • Cancer-related molecular mechanisms research
  • Histone Deacetylase Inhibitors Research
  • ATP Synthase and ATPases Research
  • NF-κB Signaling Pathways
  • Cancer-related gene regulation
  • Mitochondrial Function and Pathology
  • MicroRNA in disease regulation
  • RNA Research and Splicing
  • Neonatal Health and Biochemistry
  • Drug Transport and Resistance Mechanisms
  • Cancer-related Molecular Pathways
  • Ubiquitin and proteasome pathways
  • Circular RNAs in diseases
  • Genomics, phytochemicals, and oxidative stress
  • Immune cells in cancer
  • RNA Interference and Gene Delivery
  • Glutathione Transferases and Polymorphisms
  • Immunotherapy and Immune Responses
  • Ferroptosis and cancer prognosis
  • Trace Elements in Health

Nankai University
2012-2025

State Key Laboratory of Medicinal Chemical Biology
2018-2025

First Affiliated Hospital of Jinan University
2017-2025

Fourth Hospital of Hebei Medical University
2023

Cancer Institute (WIA)
2023

Hebei Medical University
2023

Shanghai Institute of Materia Medica
2022

Chinese Academy of Sciences
2022

Jinan University
2019-2021

Emory University
2012-2019

Abstract Ferroptosis is a newly identified iron-dependent form of death that becoming increasingly recognized as promising avenue for cancer therapy. N6-methyladenosine (m 6 A) the most abundant reversible methylation modification in mRNA contributing to tumorigenesis. However, crucial role m A regulating ferroptosis during colorectal (CRC) tumorigenesis remains elusive. Herein, we find increased ferroptotic cell and correlates with decreased demethylase fat mass obesity-associated protein...

10.1186/s13046-024-03032-9 article EN cc-by Journal of Experimental & Clinical Cancer Research 2024-04-10

Hepatitis B virus X protein (HBx) plays critical roles in the development of hepatocellular carcinogenesis (HCC). Yes-associated (YAP), a downstream effector Hippo-signaling pathway, is an important human oncogene. In present article, we report that YAP involved hepatocarcinogenesis mediated by HBx. We demonstrated expression was dramatically elevated clinical HCC samples, hepatitis (HBV)-infected hepatoma HepG2.2.15 cell line, and liver cancer tissues HBx-transgenic mice. Meanwhile, found...

10.1002/hep.25899 article EN Hepatology 2012-06-18

Hepatitis B virus X protein (HBx) plays important roles in the development of hepatocellular carcinoma (HCC). MicroRNAs (miRNAs) contribute to cancer by acting as oncogenes or tumor suppressors. Previously, we reported that HBx was able promote migration hepatoma HepG2 cells. However, regulation miRNAs HBV-related HCC is poorly understood. In present study, miR-29a a novel regulator cells mediated HBx. Our data showed expression dramatically increased p21-HBx transgenic mice, HBx-transfected...

10.1371/journal.pone.0019518 article EN cc-by PLoS ONE 2011-05-05

Abstract N6-methyladenosine (m6A) is one of widespread post-transcriptional mRNA modifications in eukaryotes and the m6A modification plays critical roles various human cancers. However, role m6A-binding proteins cancer metabolism remains elusive. Here, we report that YTH domain family 2 (YTHDF2) upregulated lung tissues, promotes cell growth enhances pentose phosphate pathway (PPP) flux, which crucial for tumor growth. Mechanistically, YTHDF2 directly binds to site 6-phosphogluconate...

10.1093/carcin/bgz152 article EN Carcinogenesis 2019-09-04

Immune cell therapy presents a paradigm for the treatment of malignant tumors. Human Vγ9Vδ2 T cells, subset peripheral γδ have been shown to promising anti-tumor activity. However, new methodology on how achieve stronger activity cells is under continuous investigation. In this work, we used selenium nanoparticles (SeNPs) strengthen cytotoxicity cells. We found SeNPs pretreated had significantly cancer killing and tumor growth inhibition efficacy when compared with alone. Simultaneously,...

10.1016/j.biomaterials.2019.119397 article EN cc-by-nc-nd Biomaterials 2019-08-13

Abstract Colorectal cancer (CRC) is among the most prevalent and deadly cancers worldwide. The Yes‐associated protein 1 (YAP1) frequently dysregulated in cancers, contributing to stemness, chemoresistance, cancer‐related death. However, strategies directly targeting YAP1 have not yet been successful because of lack active binding pockets unregulated toxicity. In this study, our Food Drug Administration (FDA)‐approved drug screening reveals that abemaciclib, a cyclin‐dependent kinase 4/6...

10.1002/mco2.70103 article EN cc-by MedComm 2025-02-17

micro RNA s are small, highly conserved, non‐coding that regulate gene expression of target m through cleavage or translational inhibition, and widely involved in carcinogenesis cancer development. In this study, the profile ‐133a (miR‐133a) was examined breast cells tissues. The results showed miR‐133a both tissues significantly down‐regulated. Over‐expression tumor arrested cell cycle by drastically decreasing G 2 /S phase retarded newly synthesized DNA , suggesting a regulatory role for...

10.1111/febs.12398 article EN FEBS Journal 2013-06-20

Cisplatin (DDP) is currently one of the most commonly used chemotherapeutic drugs for treating ovarian and lung cancer. However, resistance to cisplatin common it often leads therapy failure. In addition, precise mechanism still in its infancy. this study, we demonstrated that oxidative pentose phosphate pathway enzyme 6-phosphogluconate dehydrogenase (6PGD) promotes resistance. We showed cisplatin-resistant cancer cells (C13∗ A549DDP), had higher levels 6PGD compared their...

10.3389/fphar.2017.00421 article EN cc-by Frontiers in Pharmacology 2017-06-30

Abstract 4-hydroxyphenylpyruvate dioxygenase (HPD) is an important modifier of tyrosine metabolism. However, the precise contribution HPD to cancer metabolism and tumorigenesis remains unclear. In this study, we found that was highly expressed in lung its higher expression correlated with poor prognosis patients. Suppressed sufficient decrease oxidative pentose phosphate pathway (PPP) flux, leading reduced RNA biosynthesis enhanced reactive oxygen species (ROS) level, attenuated cell...

10.1038/s41419-019-1756-1 article EN cc-by Cell Death and Disease 2019-07-08

Copper chaperone for superoxide dismutase (CCS) is a critical component of oxidation-reduction system and functions as potential tumor promoter in several cancers. However, the function clinical significance CCS breast cancer remains unclear. Here, we found was highly expressed cancer, where it promoted cell proliferation migration. Suppression expression sufficient to attenuate phosphorylation level ERK1/2, increase accumulation reactive oxygen species (ROS). Mechanistically, that knockdown...

10.3389/fphar.2019.00356 article EN cc-by Frontiers in Pharmacology 2019-04-05

Abstract Mammalian cell nuclei contain copper, and cancer cells are known to accumulate aberrantly high copper levels, yet the mechanisms underlying nuclear accumulation copper's broader functional significance remain poorly understood. Here, by combining APEX2‐based proximity labeling focused on chaperone Atox1 with mass spectrometry we identified a previously unrecognized binding protein, Cysteine‐rich protein 2 (CRIP2), that interacts in nucleus. We show transfers CRIP2, which induces...

10.1002/anie.202108961 article EN Angewandte Chemie International Edition 2021-09-22

Metabolic reprogramming is a hallmark of cancer, including lung cancer. However, the exact underlying mechanism and therapeutic potential are largely unknown. Here we report that protein arginine methyltransferase 6 (PRMT6) highly expressed in cancer required for cell metabolism, tumorigenicity, cisplatin response PRMT6 regulated oxidative pentose phosphate pathway (PPP) flux glycolysis human by increasing activity 6-phospho-gluconate dehydrogenase (6PGD) α-enolase (ENO1). Furthermore,...

10.1016/j.apsb.2022.05.019 article EN cc-by-nc-nd Acta Pharmaceutica Sinica B 2022-05-25
Coming Soon ...